The fact that 80%–90% of lung cancer patients lack mutant EGFR and do not respond to currently available EGFR inhibitors motivates researchers to develop novel small molecule inhibitors that can effectively block both typical and mutant EGFR proteins (Gajiwala et al., 2013). This evidence concerns the gene EGFR and lung carcinoma.